The rate-limiting enzyme of the PPP, G6PD, was first suggested as a biomarker for prostate cancer over 30 years ago (24, 25), with increased G6PD activity noted in patients with prostate cancer as compared to benign prostatic hyperplasia (BPH). Here, G6PD is linked to prostate carcinoma.